

# TLCR

## TRANSLATIONAL LUNG CANCER RESEARCH

AN OPEN ACCESS JOURNAL FOCUSING ON CLOSING THE GAP BETWEEN "BENCH AND BEDSIDE"

### Annual Report 2020

Editorial Office

Email: [editor@tlcr.org](mailto:editor@tlcr.org)





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## Outline of the Report

1. Basic Information
2. Honorary Editors-in-Chief
3. Editors-in-Chief
4. Editorial Board Members
5. Publication: Number, Article Types, Internationality
6. Monthly Retrievals in PubMed (2015-2020)
7. Journal Impact Factor
8. Website Visits
9. Most Cited Articles in 2020
10. Special Series Published in 2020
11. Upcoming Special Series in 2021
12. Introduction of the Publisher AME






# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 1. Basic Information

- Open Access
- Peer Reviewed
- Launched in March 2012
- **Impact Factor: 5.132**
- Indexed by **Science Citation Index Expanded (SCIE)**, PubMed/PubMed Central, Scopus, Google Scholar, Medscape, Chemical Abstracts Service (CAS) Databases, MDlinx
- Published quarterly (Mar. 2012 - Jan. 2013), bimonthly (Feb. 2013 - Dec. 2020), and **monthly (Jan. 2021 -)**
- The first international journal focusing on closing the gap between “Bench and Bedside” in lung cancer and related thoracic diseases.





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 1. Basic Information

**TLCR is the official publication of:**

- General Hospital of Eastern Theater Command, Nanjing, China
- Society for Translational Medicine (STM), Hong Kong

**TLCR is endorsed by:**

- Spanish Lung Cancer Group (SLCG)
- Bonnie J. Addario Lung Cancer Foundation (ALCF)
- Brazilian Society of Thoracic Surgery (SBCT)



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 2. Honorary Editors-in-Chief



**Fred R. Hirsch, MD, PhD**  
Center for Thoracic Oncology,  
Tisch Cancer Institute at Mount  
Sinai, USA



**Yi-Long Wu**  
Guangdong General Hospital  
& Guangdong Academy of  
Medical Sciences, China





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 3. Editors-in-Chief



**Yong Song, MD, PhD**  
General Hospital of Eastern  
Theater Command, China



**Caicun Zhou, MD, PhD**  
Shanghai Pulmonary  
Hospital, China




**Rafael Rosell, MD, PhD**  
Dexeus University  
Institute, Spain



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 4. Editorial Board Members



**135** in totality, including:

**Two** Honorary Editors-in-Chief  
**Three** Editors-in-Chief  
**Four** Associate Editors-in-Chief  
**One** Editor Emeritus  
**Two** Associate Editor  
**123** Editorial Board Members

Updated on Dec 31, 2020






# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 5. Publication: Number



Till Dec 31, 2020, totally **1276** articles were published in TLCR.

The number of publication was increased from 2012-2014, yet it has kept a stability between 2014 and 2017, and has an obvious growth in 2020.

Updated on Dec 31, 2020






# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 5. Publication: Diverse Article Types



TLCR embraces diverse article types to meet demands from international authors and readers. The major article types published in TLCR include Original Article, Review Article and Editorial.


Updated on Dec 31, 2020



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 5. Publication: Internationality



In total, **256** Corresponding Authors from **25** countries and regions contributed to TLCR in 2020, with the majority from **China and USA**.


Updated on Dec 31, 2020



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 6. Monthly Retrievals in PubMed (2015-2020)



This year, retrieval number of TLCR in PMC has reached up to a total of **833,627** times.

Source: PubMed Central





# TLCR


TRANSLATIONAL LUNG CANCER RESEARCH

## 7. Journal Impact Factor

2019 Journal Impact Factor & percentile rank in category for: Translational Lung Cancer Research

**5.132**

2019 Journal Impact Factor




Source: Web of Science Core Collection



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 8. Website Visits



Country	Sessions	% Sessions
1.  United States	64,903	30.15%
2.  China	40,253	18.70%
3.  India	12,794	5.94%
4.  Japan	12,200	5.67%
5.  United Kingdom	9,897	4.60%
6.  South Korea	6,397	2.97%
7.  Italy	5,972	2.77%
8.  Australia	5,582	2.59%
9.  Canada	5,094	2.37%
10.  Germany	4,724	2.19%

According to the data collected from Google Analytics, there are altogether **144,474** users and **512,594** pageviews in 2020. Readers who visited TLCR website form diverse countries, with the majority from United States, followed by China, India, Japan and United Kingdom.

Source: Google Analytics



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 9. Most Cited Articles in 2020

Corresponding Author	Article Title
Shaker A. Mousa	Non-small cell lung cancer: current treatment and future advances
Patricia M. de Groot	The epidemiology of lung cancer
Brett G.M. Hughes	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future
Jeryl Villadolid	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities
Nicky D'Haene	Methods of measurement for tumor mutational burden in tumor tissue
Farhad Islami	Global trends of lung cancer mortality and smoking prevalence
Fabrice Barlesi	The clinical utility of tumor mutational burden in non-small cell lung cancer
Ming-Sound Tsao	Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review
Takashi Kohno	Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer
Albrecht Stenzinger	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians

Source: Web of Science Core Collection





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 10. Special Series Published in 2020

➤ **“Mesothelioma: What We know and What We Do Not Know in 2020”** edited by



**Michele Carbone, MD, PhD**

University of Hawai'i Cancer Center,  
Honolulu, USA



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 10. Special Series Published in 2020

➤ “Lung Cancer Multidisciplinary Care” edited by



**Emily Stone, MD, PhD**

St Vincent's Hospital Sydney, Kinghorn  
Cancer Centre, University of Sydney,  
Sydney, Australia



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 10. Special Series Published in 2020

- **“Selected Highlights of the 2019 Pulmonary Pathology Society Biennial Meeting”**  
edited by



**Sanja Dacic, MD, PhD**

University of Pittsburgh Medical Center,  
Pittsburgh, USA





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 10. Special Series Published in 2020

- **“New Developments in Lung Cancer Diagnosis and Pathological Patient Management Strategies”** edited by



**Helmut Popper, MD**

Medical University of Graz,  
Graz, Austria



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 10. Special Series Published in 2020

- **“Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions”** edited by



**Silvia Novello, MD, PhD**

University of Turin, San Luigi Hospital,  
Orbassano, Italy



**Francesco Passiglia, MD, PhD**

University of Turin, San Luigi Hospital,  
Orbassano, Italy



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 11. Upcoming Special Series in 2021

**“Multimodal management of locally advanced N2 non-small cell lung cancer” edited by**



**Mariano Provencio, MD, PhD**

Hospital Universitario Puerta de Hierro,  
Madrid, Spain





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 11. Upcoming Special Series in 2021

➤ “Lung cancer screening” edited by



**Paul Van Schil, MD, PhD**  
Antwerp University Hospital,  
Antwerp, Belgium



**Annemiek Snoeckx, MD, PhD**  
Antwerp University Hospital,  
Antwerp, Belgium



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 11. Upcoming Special Series in 2021

➤ **“Radiotherapy in thoracic malignancies” edited by**



**Jacek Jassem, MD, PhD**  
Medical University of Gdańsk,  
Gdańsk, Poland.



**Rafal Dziadziuszko, MD, PhD**  
Medical University of Gdańsk,  
Gdańsk, Poland.




# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 11. Upcoming Special Series in 2021

- **“Immunotherapy in other thoracic malignancies and uncommon populations”**  
edited by



**Jordi Remon, MD**  
Hospital HM Delfos, HM  
Hospitales, Barcelona, Spain



**Benjamin Besse, MD, PhD**  
Université Paris-Saclay, Villejuif,  
France





# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 11. Upcoming Special Series in 2021

➤ **“Implementation of CT-based screening of lung cancer” edited by**



**Witold Rzyman, MD, PhD**  
Medical University of Gdansk,  
Gdańsk, Poland



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 11. Upcoming Special Series in 2021

➤ **“Lung Cancer & The Immune System”** edited by



**Daniel Steinfort, MBBS, BMedSci, FRACP, PhD**

University of Melbourne,  
Melbourne, Australia



# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

## 12. Introduction of the Publisher AME

Our Publisher—

**AME Publishing Company**

[www.amegroups.com](http://www.amegroups.com)

- Established in 2009
- Registered in Hong Kong
- 10 offices around the world
- 60+ peer-reviewed journals
  - 13 indexed in SCIE
  - 18 indexed in PubMed/PMC/MEDLINE
- 200+ Medical Books
  - 80+ Medical Books in English
  - 120+ Medical Books in Chinese
  - 150+ Electronic Editions

AME JOURNALS







# TLCR

TRANSLATIONAL LUNG CANCER RESEARCH

*Thank You for All Your Support!*